Rakesh Dixit
President & Chief Executive Officer Bionavigen Oncology
Rakesh Dixit is an accomplished executive, inventor, and scientist with over 30 years of success with top biotechnology and pharmaceutical companies, including Merck, Johnson & Johnson, MedImmune, and AstraZeneca.
Rakesh highly respected global leader known for building highly motivated safety assessment teams to advance small and large molecule biologics drug development programs and achieve company goals. He is a key opinion leader in translation sciences, safety, pharmacology, and drug developmentwith outstanding knowledge and proven experience in drug discovery, the preclinical, and clinical outcome from IND/CTA, phase I, II, III, BLA/MAA, and approval.
Seminars
Even with 2026 seeing ADCs continue to rival oncology standard of care performance, translation of ADC toxicity profiles to the clinic remains the largest hurdle to widen ADC therapeutic index and accomplish widespread impact for patients in need.
Led by long-standing ADC toxicity experts, join your peers to understand ADC class effect toxicities and best leverage preclinical tools and historical learnings to effectively characterize safety profiles and predict ADC tolerability in the clinic.
Workshop highlights include:
- Discussing ADC class effect toxicities observed in the clinic across ocular toxicity, ILD, neutropenia and beyond
- Delving into deployment and utilization of in vivo and in vitro models to improve prediction of clinical toxicity profiles
- Breaking down lessons learned from successful and failed historical ADC translation to inform design, engineering and characterization of better ADCs with wider therapeutic index
- Understanding the need for ADC novelty to overcome patient resistance and deliver differentiated tolerability to widen therapeutic index
- Evaluating the tolerability of ISACs and AOCs to assess the risk benefit profiles of alternate payload mechanisms
- Understanding how considerations across bystander activity and target selection are crucial to manager toxicity of bispecific and peptide drug conjugates
